An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL

Enrollment

462

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

July 31, 2008

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG

VIAject™

Dosage as individually required

DRUG

Regular Human Insulin

Dosage as individually required